Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study
Autor: | Avi I. Einzig, Chandra P. Belani, T. Dobbs, Slawomir Wojtowicz-Praga, P. Bonomi, Sakkaraiappan Ramalingam, Marianne Cascino |
---|---|
Rok vydání: | 2004 |
Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment non-small cell lung cancer (NSCLC) Docetaxel Toxicology Carboplatin chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Lung cancer neoplasms Survival rate Aged Pharmacology Chemotherapy business.industry Middle Aged medicine.disease Surgery Regimen chemistry Area Under Curve Female Taxoids business Febrile neutropenia medicine.drug |
Zdroj: | Cancer Chemotherapy and Pharmacology. 53:439-444 |
ISSN: | 1432-0843 0344-5704 |
DOI: | 10.1007/s00280-003-0752-3 |
Popis: | To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer. In a phase II study, patients with inoperable stage IIIB or stage IV non-small-cell lung cancer (ECOG performance status of 0 or 1) were treated with the combination of carboplatin AUC 5 mg/ml·min and docetaxel 80 mg/m2 administered once every 3 weeks. A total of 45 patients were accrued to the study. The median age was 62 years and adenocarcinoma was the most common histology. Patients received a median of four cycles of chemotherapy. The objective response rate was 29% with a median survival of 11.9 months among evaluable patients. The 1-year survival rate was 47%. Febrile neutropenia (17%) was the most common hematological toxicity associated with the regimen whereas grade 3 fatigue (4%) was the major nonhematological toxicity. The combination of carboplatin plus docetaxel is well tolerated and is effective for the treatment of patients with previously untreated advanced or metastatic non-small-cell lung cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |